TY - JOUR
T1 - Brain metastasis as exclusion criteria in extensive-stage small cell lung cancer trials
T2 - a trend over decades
AU - Komiya, Takefumi
AU - Chaaya, Gerard
AU - Deshotels, Leigh
AU - Powell, Emily
AU - Guddati, Achuta Kumar
N1 - Publisher Copyright:
© The Author(s) 2020.
PY - 2020
Y1 - 2020
N2 - Aim: To investigate the frequencies and trends of brain metastases (BMs) as exclusion criteria in extensive-stage small cell lung cancer (ES-SCLC) trials. Methods: We conducted a comprehensive search to identify prospective clinical trials in patients with ES-SCLC. PubMed searches were conducted with the key words "small cell lung cancer"and "extensive". The online archives of 20 oncology journals were also searched. Recent review articles in ES-SCLC were also investigated for additional articles. Eligible studies must have enrolled primarily ES-SCLC and been published in English. Studies involving brain/chest radiation and brain metastasis-specific trials were excluded. Studies were categorized into allowed/ undefined, conditional, or complete exclusion of BM. Results: In total, 491 published studies were identified by PubMed (240), journal websites (198), and review articles (53). Early publication year (1970-1999) and first-line/maintenance setting were associated with higher incidence of complete exclusion of cases with BMs (P < 0.0001 and 0.0233, respectively). Incidence of complete exclusion was 27% in the 1990s, and then decreased to 12% in the 2000s and 8% in the 2010s. Conclusion: A significant number of ES-SCLC trials continues to exclude patients with BM. Future studies need to ease eligibility regarding BM according to ASCO/Friends recommendations.
AB - Aim: To investigate the frequencies and trends of brain metastases (BMs) as exclusion criteria in extensive-stage small cell lung cancer (ES-SCLC) trials. Methods: We conducted a comprehensive search to identify prospective clinical trials in patients with ES-SCLC. PubMed searches were conducted with the key words "small cell lung cancer"and "extensive". The online archives of 20 oncology journals were also searched. Recent review articles in ES-SCLC were also investigated for additional articles. Eligible studies must have enrolled primarily ES-SCLC and been published in English. Studies involving brain/chest radiation and brain metastasis-specific trials were excluded. Studies were categorized into allowed/ undefined, conditional, or complete exclusion of BM. Results: In total, 491 published studies were identified by PubMed (240), journal websites (198), and review articles (53). Early publication year (1970-1999) and first-line/maintenance setting were associated with higher incidence of complete exclusion of cases with BMs (P < 0.0001 and 0.0233, respectively). Incidence of complete exclusion was 27% in the 1990s, and then decreased to 12% in the 2000s and 8% in the 2010s. Conclusion: A significant number of ES-SCLC trials continues to exclude patients with BM. Future studies need to ease eligibility regarding BM according to ASCO/Friends recommendations.
UR - http://www.scopus.com/inward/record.url?scp=85174354735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174354735&partnerID=8YFLogxK
U2 - 10.20517/2394-4722.2019.41
DO - 10.20517/2394-4722.2019.41
M3 - Article
AN - SCOPUS:85174354735
SN - 2394-4722
VL - 6
JO - Journal of Cancer Metastasis and Treatment
JF - Journal of Cancer Metastasis and Treatment
M1 - 3356
ER -
